CYTK Jan 2025 135.000 call
- GuruFocus.com
Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)
Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion.
- GuruFocus.com
Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company.
- GlobeNewswire
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. “We are conducting this Phase 1 bridging study to characterize the pharmacokinetics of aficamten in healthy Japanese adults and to gather evidence that we believe will be required for potential appr
